48 completed, 18 unknown, 9 active not recruiting, 8 recruiting. 94 Phase 3, 7 Phase 2.
Follow Ifosfamide: new trials by email Literature Review of Ifosfamide trials Research Report on Ifosfamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma Biospecimen Collection, Bone Scan, Computed Tomography - Pleuropulmonary Blastoma | Phase 3 | Recruiting | Children's Oncology Group | 110 | 2025-03-21 | 2026-08-25 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 216 | 2024-02-15 | 2026-05-11 |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 3 | Withdrawn | National Cancer Institute (NCI) | 2023-08-10 | 2024-03-20 | |
| Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide - T-cell Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Cancer Group, China | 200 | 2023-02-06 | 2026-03-19 |
| Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | GWT-TUD GmbH | 306 | 2021-04-30 | 2026-06-10 |
| High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Vincristine, Carboplatin, Etoposide - High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 800 | 2019-11-05 | 2025-06-26 |
| A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy Sintilimab, Carboplatin, Etoposide - Classic Hodgkin's Lymphoma | Phase 3 | Unknown | Innovent Biologics (Suzhou) Co. Ltd. | 240 | 2019-10-21 | 2022-09-14 |
| International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Lymphoblastic Lymphoma, Childhood | Phase 3 | Recruiting | University Hospital Muenster | 683 | 2019-08-23 | 2026-05-06 |
| Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator - Non-metastatic Soft-tissue Sarcoma, Resectable | Phase 3 | Recruiting | Institut BergoniƩ | 351 | 2019-02-14 | 2025-10-02 |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Blinatumomab, Bortezomib, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric | Phase 3 | Recruiting | Martin Schrappe | 5000 | 2018-07-15 | 2025-04-06 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Rituximab window, Additional doses of Rituximab, Cyclophosphamide - Mature B-cell Non-Hodgkin Lymphoma | Phase 3 | Active not recruiting | University Hospital Muenster | 650 | 2017-08-03 | 2026-04-30 |
| SIMPLE Chemotherapy for NK Lymphoma/Leukaemia Cisplatin, Gemcitabine, Etoposide (VP-16) - Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin T-cell Lymphoma | Phase 3 | Unknown | The University of Hong Kong | 68 | 2017-07-01 | 2018-08-14 |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide - Squamous Cell Carcinoma of the Penis, Usual Type | Phase 3 | Active not recruiting | Institute of Cancer Research, United Kingdom | 200 | 2017-05-12 | 2026-08-31 |
| A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Ibrutinib, Rituximab, Ifosfamide - Lymphoma, Non-Hodgkin | Phase 3 | Terminated | Janssen Research & Development, LLC | 72 | 2016-07-01 | 2022-12-02 |
Showing 20 of 94. Sign in to see all of them.
Sarcoma (23) · Fibrosarcoma (9) · Liposarcoma (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Hemangiosarcoma (8) · Lymphoma (8) · Histiocytoma, Malignant Fibrous (7) · Leiomyosarcoma (7) · Lymphoma, Large B-Cell, Diffuse (7) · Neurofibrosarcoma (7) · Sarcoma, Synovial (7) · Hemangiopericytoma, Malignant (6) · Leukemia (6) · Malignant mesenchymal tumor (6) · Rhabdomyosarcoma (6)
Children's Oncology Group (14) · National Cancer Institute (NCI) (9) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Gustave Roussy, Cancer Campus, Grand Paris (4) · UNICANCER (3) · University Hospital Muenster (3) · Alliance for Clinical Trials in Oncology (2) · Children's Cancer Group, China (2) · Children's Cancer and Leukaemia Group (2) · European Lung Cancer Working Party (2) · European Paediatric Soft Tissue Sarcoma Study Group (2) · German Society for Pediatric Oncology and Hematology GPOH gGmbH (2) · Gynecologic Oncology Group (2) · Italian Sarcoma Group (2) · M.D. Anderson Cancer Center (2)
United States (37) · United Kingdom (25) · Germany (24) · Switzerland (23) · Australia (22) · France (22) · Canada (21) · Spain (19) · Belgium (18) · Netherlands (18) · Austria (16) · Italy (13) · Puerto Rico (13) · Denmark (12) · Sweden (12)
Alan W. Craft, MD (2) · Birgit Burkhardt, Prof. Dr. Dr. (2) · Frank Berthold, MD (2) · Heribert F. Juergens, MD (2) · Higinia R. Cardenes, MD, PhD (2) · Ian R. Judson, MA, MD, FRCP (2) · Jean-Paul Sculier, MD, PhD (2) · Laurence Brugieres, MD (2) · A.N. Van Geel, MD (1) · Aaron H. Wolfson, MD (1) · Aaron R Weiss (1) · Adrian Hodson (1) · Amos Burke (1) · Andrea Biondi (1) · Andrea Ferrari, MD (1)
PMID 33242441, PMID 16421426, PMID 19433688, PMID 20154213, PMID 21719599, PMID 24344215, PMID 26888258, PMID 26913693, PMID 29148893, PMID 31401903, PMID 31601692, PMID 33152759, PMID 35271306, PMID 37021527, PMID 37505794, PMID 10499612, PMID 10627444, PMID 10882162, PMID 11426549, PMID 11464889, PMID 12101494, PMID 12165894, PMID 12880954, PMID 12932669, PMID 16129365, PMID 16157935, PMID 16293867, PMID 16572419, PMID 17003366, PMID 17290061, PMID 17544497, PMID 17634494, PMID 17761975, PMID 17822748, PMID 17971487, PMID 18239620, PMID 18780832, PMID 18802150, PMID 19546402, PMID 19760772, PMID 20108339, PMID 20308673, PMID 20434400, PMID 20547982, PMID 20660832, PMID 20679620, PMID 20694800, PMID 20944675, PMID 21059637, PMID 21280197
U10CA098543 (10), U10CA180886 (8), 2017 (2), U10CA180821 (2), U10CA180830 (2), 2004 (1), 2005 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), P30CA013330 (1), P30CA016672 (1), U10CA027469 (1)